title: Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control.
abstract: Two hundred thirty-six patients with T3 bladder cancer who survived radical surgery and proved to have P3a, P3b, or P4a tumors were randomized in two phases into three groups: (a) no further treatment (83 patients); (b) postoperative radiotherapy multiple daily fractionation (MDF), using 3 daily fractions of 1.25 Gy each, with 3 hr between fractions, up to a total dose of 37.5 Gy in 12 days (75 patients); and (c) postoperative radiotherapy conventional fractionation (CF), for a total dose of 50 Gy/5 weeks (78 patients). The tolerance of the patients to postoperative radiotherapy was quite acceptable, with equal acute reactions in MDF and CF groups. The 5-year disease-free survival (DFS) rates amounted to 49 and 44% in MDF and CF postoperative radiotherapy groups, respectively, compared to 25% in the cystectomy-alone group. The 5-year local control rates were 87% and 93% for those treated with multiple daily fractionation and conventional fractionation while it was 50% in the surgery-alone group. The therapeutic benefit of postoperative irradiation was consistent for all tumor types, histological grades, and pathological stages for both the disease-free survival and local control. Patients with nodal metastases demonstrated lower recurrence rates in the postoperative radiotherapy groups, but this was not associated with improved disease-free survival. Multivariate analysis using the Cox Model confirmed these results. The independent prognostic factors affecting both disease-free survival and local control were the addition of postoperative radiotherapy, the nodal status, the pathological stage, and the tumor grade. Late complications of radiotherapy in the skin, small intestine, rectum, and the anastomotic site of the urinary division were lower with MDF than with conventional fractionation.
authors.affiliation: Dept. of Radiotherapy, National Cancer Institute, Cairo, Egypt.
authors.forename: M S
authors.initials: MS
authors.lastname: Zaghloul
authors.forename: H K
authors.initials: HK
authors.lastname: Awwad
authors.forename: H H
authors.initials: HH
authors.lastname: Akoush
authors.forename: S
authors.initials: S
authors.lastname: Omar
authors.forename: O
authors.initials: O
authors.lastname: Soliman
authors.forename: I
authors.initials: I
authors.lastname: el Attar
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D011897:Random Allocation; D012552:Schistosomiasis / Q000628:therapy*; D001745:Urinary Bladder Diseases / Q000628:therapy*; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000532:radiotherapy*